Teo KYC, Jordan-Yu JM, Tan ACS, et al. - Researchers conducted a 52-week, randomized, open-label, non-inferiority, single-centre study including 53 participants with symptomatic polypoidal choroidal vasculopathy (PCV) with the aim to compare the efficacy of aflibercept using a personalised vs fixed regimen in these patients. Per outcomes, non-inferior best-corrected visual acuity gain and numerically higher polypoidal lesions closure were achieved with personalised regimen when compared with fixed regimen.